Quantifying the costs of serious adverse drug reactions to antiepileptic drugs

Epilepsia

Volumn 39, Issue SUPPL. 7, 1998, Pages

  Schlienger, Raymond G ^a   Oh, Paul I ^a   Knowles, Sandra R ^a   Shear, Neil H ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Adverse drug reactions; Antiepileptic drugs; Costs; Hypersensitivity; Skin

Indexed keywords

ANTICONVULSIVE AGENT;

ANTICONVULSANT THERAPY; ARTICLE; COST BENEFIT ANALYSIS; DRUG COST; DRUG HYPERSENSITIVITY; EPILEPSY; HEALTH CARE COST; HUMAN; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTICONVULSANTS; DIRECT SERVICE COSTS; DRUG COSTS; DRUG HYPERSENSITIVITY; EPILEPSY; FEMALE; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; ONTARIO; PHENYTOIN; RETROSPECTIVE STUDIES; SEIZURES; VALPROIC ACID;

EID: 0031791816     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1998.tb01682.x     Document Type: Article

References (26)

1. Mach E, Venulet J. The economics of adverse reactions to drugs. WHO Chronicle 1975;29:79-84.
2. Brodie M, Dichter M. Antiepileptic drugs. N Engl J Med 1996; 334:168-75.
3. Keck P, McElroy S, Nemeroff C. Anticonvulsants in the treatment of bipolar disorder. J Neuropsychiatry Clin Neurosci 1992;4:395-405.
4. Pope H, McElroy S, Keck P, Hudson J. Valproate in psychiatric disorders: literature review and clinical guidelines. J Clin Psychiatry 1991;48:62-8.
5. Chang D, Shear N. Cutaneous reactions to anticonvulsants. Semin Neurol 1992;12:329-37.
6. Collaborative Group for Epidemiology of Epilepsy. Adverse reactions to antiepileptic drugs: a multicentre survey of clinical practice. Epilepsia 1986;27:323-30.
7. Cloyd J, Brundage R. Valproic acid. In: Taylor W, Diers Caviness M, eds. A textbook for the clinical application of therapeutic drug monitoring. Irving, TX: Abbott Laboratories. Diagnostic Division, 1986:269-80.
8. Mattson R, Cramer J. Phenobarbital toxicity. In: Woodbury DM, Pippenger CE. eds. Antiepileptic drugs. New York: Raven Press, 1982:351-63.
9. Silverman A, Fairley J, Wong R. Cutaneous and immunologic reactions to phenytoin. J Am Acad Dermatol 1988;18:721-41.
10. Pellock JM. Carbamazepine side effects in children and adults. Epilepsia 1987;28(Suppl 3):S64-70.
11. Shear N, Spielberg S. Anticonvulsant hypersensitivity syndrome. J Clin Invest 1988;82:1826-32.
12. Tennis P, Stern RS. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology 1997;49:542-6.
13. Grant S, Heel R. Vigabatrin. Drugs 1991;41:889-926.
14. Dichter M, Brodie M. New antiepileptic drugs. N Engl J Med 1996;334:1583-90.
15. Hughes D, Cockerell O. A cost minimization study comparing vigabatrin, lamotrigine and gabapentin for the treatment of intractable partial epilepsy. Seizure 1996;5:89-95.
16. PMIC. International Classification of Diseases. 9th rev. Clinical Modification. 4th ed. Los Angeles: Practice Management Information Corp., 1996.
17. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
18. Schneider P, Gift M, Rothermich E. Sill B. Cost of medication-related problems at a university hospital. Am J Health System Pharm 1995;52:2415-8.
19. Evans R, Classen D, Stevens L, et al. Using a hospital system to assess the effects of adverse drug events. Proc Annu Symp Comput Appl Med Care 1993;17:161-5.
20. Classen D, Pestotnik S, Evans R, Lloyd J, Bruke J. Adverse drug events in hospitalized patients. JAMA 1997;277:301-6.
21. Campistol J, Geli M, Llistosella E, Molins J, Llobet M. Sindrome de Stevens-Johnson tras la introduccion de lamotrigina. Rev Neurol 1995;23:1236-8.
22. Jones D, Chhiap V, Resor S, Appel G. Grossman ME. Phenytoin-like hypersensitivity associated with lamotrigine. J Am Acad Dermatol 1997;36:1016-8.
23. Nicholson RJ, Kelly KP, Grant IS. Leucopenia associated with lamotrigine. BMJ 1995;310:504.
24. Sullivan JR, Watson A. Lamotrigine-induced toxic epidermal necrolysis treated with intravenous cyclosporin: a discussion of pathogenesis and immunosuppressive management. Australas J Dermatol 1996;37:208-12.
25. Sachs E, Rönnau AC, von Schmiedeberg S, Ruzicka T, Gleichmann E, Schuppe H-C. Lamotrigine-induced Stevens-Johnson syndrome: demonstration of specific lymphocyte reactivity in vitro. Dermatology 1997;195:60-4.
26. Dukes M. Economic costs of adverse drug reactions. Pharmacoeconomics 1992;1:153-4.